Profile data is unavailable for this security.
About the company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
- Revenue in USD (TTM)0.00
- Net income in USD-135.31m
- Incorporated2019
- Employees157.00
- LocationIteos Therapeutics Inc321 Arsenal StreetBldg 312, Floor 3, Suite 301WATERTOWN 02472United StatesUSA
- Phone+1 (857) 204-4583
- Fax+1 (302) 655-5049
- Websitehttps://www.iteostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNDL Inc | 663.66m | -100.16m | 578.29m | 2.52k | -- | 0.6518 | -- | 0.8714 | -0.3826 | -0.3915 | 2.54 | 3.41 | 0.5855 | 4.67 | 33.35 | 263,776.10 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Zymeworks Inc | 50.46m | -125.97m | 599.58m | 275.00 | -- | 1.38 | -- | 11.88 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Erasca Inc | 0.00 | -126.86m | 599.72m | 126.00 | -- | 1.32 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Hillevax Inc | 0.00 | -143.51m | 603.61m | 90.00 | -- | 2.49 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| iTeos Therapeutics Inc | 0.00 | -135.31m | 604.70m | 157.00 | -- | 1.11 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 606.13m | 102.00 | -- | 1.84 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 614.46m | 285.00 | -- | 1.45 | -- | 265.88 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| PetIQ Inc | 1.12bn | 7.34m | 617.65m | 1.93k | 96.28 | 2.61 | 11.39 | 0.5515 | 0.2156 | 0.2156 | 36.40 | 7.95 | 1.29 | 4.58 | 5.67 | 579,376.60 | 0.8933 | -4.32 | 1.14 | -5.23 | 23.66 | 20.05 | 0.6951 | -3.66 | 1.25 | 1.84 | 0.6517 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 617.88m | 38.00 | -- | -- | -- | 23.85 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 632.48m | 57.00 | -- | 3.19 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 634.01m | 28.00 | -- | 1.93 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 634.09m | 73.00 | -- | 5.28 | -- | 48.83 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 634.24m | 53.00 | -- | 1.70 | -- | 196.73 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Harrow Inc | 138.68m | -31.33m | 635.11m | 315.00 | -- | 10.49 | -- | 4.58 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 641.47m | 52.00 | -- | 11.91 | -- | 45.31 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Iteos Therapeutics Inc's reporting currency: US Dollar USD
44.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 10 May 2024 | 3.66m | 10.21% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.70m | 7.52% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 2.00m | 5.58% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.48m | 4.13% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.46m | 4.08% |
| Braidwell LPas of 31 Mar 2024 | 1.16m | 3.24% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.00m | 2.80% |
| Millennium Management LLCas of 31 Mar 2024 | 882.98k | 2.46% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 791.17k | 2.21% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 717.30k | 2.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
